A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19
Samir Gupta, MD
Primary Investigator
Overview
The purpose of this study is to provide remdesivir (RDV) to participants with severe COVID-19.
Description
Participants will be randomly assigned to either continued standard of care therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2-5, or continued standard of care therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2-10.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
COVID-19
-
Age: Between 18 Years - 100 Years
-
Gender: All
Individuals at least 18 years of age hospitalized with a confirmed case of COVID-19.
Individuals with evidence of multiorgan failure, or those who have been mechanically ventialated for 5 or more days will not be eligible.
Women who are pregnant or breastfeeding will not be eligible.